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Abstract 
 
Inter-individual differences in drug response are an important cause of failure in anticancer treatment 
and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been 
investigated in an effort to find new genetic biomarkers to predict toxicity and response to anticancer 
drugs. Evaluating the value single nucleotide polymorphisms (SNPs) in the genes involved in 
transportation, activation and metabolism of anticancer drugs provides a promising approach to select 
the appropriate therapeutic regimes with at least adverse reactions. This review summarizes the 
current knowledge about the relationship between of SNPs involved in the transportation, activation 
and metabolism of anticancer drugs and treatment outcomes in colorectal cancer (CRC) patients.  
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 Introduction 
Colorectal cancer (CRC) is one of the most common causes of cancer related death globally 
(Moradi‐Marjaneh, Hassanian et al. 2017). Chemotherapeutic drugs, radiation therapy and surgical 
resection are approaches to improve the patient’s survival rate(Bahrami, Hassanian et al. 2017). 
Despite advances in the treatment of CRC, a large percentage of patients still die of the 
disease(Rahmani, Avan et al. 2017). The treatment outcomes vary. Additionally, adverse drug reactions 
are very variable, so that some patients successfully complete treatment cycles, whilst in others 
treatment must be discontinued due to life threatening complications(Plumpton, Roberts et al. 2016). 
Therefore, there is an urgent need to identify biomarkers that are able to tailor an appropriate drug for 
the CRC patient. 
The importance of pharmacogenetics in the drug management of CRC patient was not recognised for a 
long time, but there has been a recent interest in personalized medicine. Pharmacogenetics is 
promising for the identification of patients with a high risk of side effects, and to design an effective 
treatment regime based on individual's characteristics(Bruun, Eide et al. 2017). Single Nucleotide 
Polymorphisms (SNPs) may play an important role in the identification of susceptibility to various 
diseases and responses to treatment(Wheeler, Maitland et al. 2013). The identification of specific SNPs 
from the large number that has the potential for predicting treatment outcomes and possible toxicity is 
manifestly essential before using them in clinic. For this purpose, candidate-gene association studies 
have been a useful approach to identify some of these variants. Genome-wide association studies 
(GWAS) also have a value in identifying the variants and their association with treatment 
outcomes(Fernandez-Rozadilla, Cazier et al. 2013). 
The efficacy and toxicity of anticancer drugs in cancer cells depend on various factors, including the 
effective concentration of drug in the cell and the efficiency of enzymes activating/metabolizing 
anticancer drug. The effective concentration of anticancer drug in cancer cells is dependant on the cell 
membrane transporters(J Liu, Lu et al. 2012). In addition, many anticancer drugs are not potentially 
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active and enzymes responsible for drug activating are needed. Also, the toxicity of the systemic 
administration of therapy is influenced by the processes involved in the metabolism of the 
drug(Mitselou, Ioachim et al. 2012, Dean 2016).  
The aim of this study was to summarize the genetic variation in genes which their products regulate the 
activation, metabolism and concentration of CRC anticancer drugs in cancer cells, in order to introduce 
informative polymorphism markers such as SNPs for implementation into clinical use as a assisting to 
select the best chemotherapeutic strategy for CRC patients with the most sensitivity and the least 
toxicity. 
SNPs of genes involved in Anticancer Drug Transporter 
Membrane transporters proteins including ATP-binding cassette (ABC) and the solute carrier (SLC), play 
an important role in processes involved in anti-cancer drug pharmacokinetic; absorption, distribution, 
metabolism and elimination or excretion (ADME). In addition there has been increasing evidence that 
ABCs and SLCs play an important role in the biology of various cancers including CRC. ABCs and SLCs are 
also strongly involved in multi-drug resistance (MDR)(Januchowski, Zawierucha et al. 2013). Low 
accumulation of anti-cancer drugs in cancer cells may be as a result of drug efflux, mediated by ABC 
transporters, or decreased drug uptake into the cancer cells, mediated by SLC transporters(De Mattia, 
Toffoli et al. 2013). 
There is growing evidence showing the importance of single nucleotide polymorphisms (SNPs) of ABCs 
and SLCs in determining inter-interindividual differences of pharmacokinetics of a variety of anti-cancer 
drugs(Ab Mutalib, Yusof et al. 2017). This variability is also related to significant differences in 
treatment outcome and severe unpredictable toxicity in some patients(Di Martino, Arbitrio et al. 2011).  
ATP-binding cassette (ABC) transporters 
ATP-binding cassette (ABC) transporters mediate multidrug resistance (MDR) through 
chemotherapeutic drugs efflux(Wu, Kang et al. 2013). There is growing evidence indicates that the 
analysis of polymorphism in ABC genes could be employed as a potential approach to predict 
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chemotherapy outcomes and possible toxicity in CRC patients. A case–control study has evaluated the 
relationship between ABCB1 polymorphisms and risk of CRC and clinical outcomes following 
chemotherapeutic regimes in 1028 CRC patients and 1230 controls. The CT rs1045642 and GT/A 
rs2032582 SNPs were associated with an increased risk of CRC. In addition the TT rs1128503-TT 
rs2032582-TT rs1045642 haplotypes were associated with worse PFS. But the presence of the CT 
rs1128503 SNP was related to a longer OS after oxaliplatin-based chemotherapy(Wu, Kang et al. 2013) 
A further study confirmed that genetic variations in ABCB1 are related to early toxicity and lower 
response to irinotecan and 5-FU treatment. So that TTrs1045642 was related to an increased risk of 
early toxicity in irinotecan and 5-FU-treated CRC patients. Also carriers of the T rs1128503-T rs2032582-
T rs1045642 haplotype were less sensitive and had shorter OS(Glimelius, Garmo et al. 2011). Patients 
with the homozygous genotype of CC rs562 in ABCC5 gene and GG rs425215 in ABCG1 gene had an 
increased susceptibility to gastrointestinal toxicity following irinotecan therapy in metastatic CRC 
patients(Di Martino, Arbitrio et al. 2011).  Mattiaa et al indicate that C>T rs7699188 polymorphism in 
ABCG2 gene and G>T/A rs2032582 polymorphism in ABCB1 gene are predictive of the response to 
treatment and patient OS respectively(De Mattia, Toffoli et al. 2013). Also the CC rs717620 in ABCC2 
gene was found o be related to longer PFS and efficacy of first-line FOLFIRI in advanced CRC 
patients(Akiyama, Fujita et al. 2012). In addition carriers of GT rs2032582 ABCB1 gene who received 
irinotecan monotherapy or irinotecan–cisplatin-combination had higher SN-38 (active metabolic of 
irrinotecan) levels (Sai, Saito et al. 2010).  
 Contrary to the results of the above studies, Falkowski et al did not find any associations between CRC 
and SNPs in ABCB1 and ABCC2 genes in 300 CRC patients and 300 matched controls. but, they did 
report a relationship between environmental risk factors and CRC so that carriers of ABCB1 rs1045642-
T (exon26) variant allele in the subgroup that had never consumed alcohol had an increased risk of CRC 
(Falkowski, Woillard et al. 2017). Custodio et al study also showed a significant association between 
polymorphisms of rs1045642 in ABCB1 gene and rs2231142, rs2728124 and rs3114018 in ABCG2 gene 
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and outcome of chemotherapy in patients with stage II and III colon cancer(Custodio, Moreno-Rubio et 
al. 2014). Another study evaluated the relationship between rs1045642  and risk of recurrence in CRC 
patients treated by 5FU and leucovorin and did not find any correlation(Huang, Fang et al. 2008). 
Kap et al design a model of 1,444 SNPs to find a predictive markers for oxaliplatin treatment. Finally 
they chose 14 SNPs from eight genes (ABC transporters, ATPases and Metabolizers). Minor alleles of 
rs1642763 in ATP1B2 gene, rs8100856 in ATP8B3 gene and rs11807 in GSTM5 gene were associated 
with an increased risk of death in the patients who treated with oxaliplatin, while the contrary 
association was observed in patients who were not treated with oxaliplatin. Carriers of the minor allele 
of rs2125739 in ABCC10 gene and rs7249302 in ATP8B3 gene who received oxaliplatin had a small risks 
of mortality (Kap, Seibold et al. 2016). 
Solute carrier (SLC) transporters 
The organic-anion-transporting polypeptide (OATP/SLCO) gene belongs to the SLC transporter gene 
family. It has been proposed that the OATP/SLCO polymorphisms can be used to predict the treatment 
outcomes in CRC patients. The solute carrier organic anion transporter family member 1B1 
(SLCO1B1) gene encodes for a protein called organic anion transporting polypeptide 1B1 
(OATP1B1)(Romaine, Bailey et al. 2010). The heterozygous genotype of GA rs2306283 in 
OATP1B1/SLCO1B1 was related to increased gastrointestinal toxicity following irinotecan therapy in 
patients with metastatic CRC (Di Martino, Arbitrio et al. 2011). Furthermore Huang1 et al selected 3 
SNPs in SLCO/ OATP gene and genotyped 137 metastatic CRC patients. They showed that GA/AA 
rs2306283 in SLCO1B1 gene and GG rs1051266 in SLC19A1 gene were associated with a higher rapid 
response rate. GA/AA rs2306283 in SLCO1B1 gene was also an independent prognostic factor for a 
longer PFS(Huang, Zhang et al. 2013). However Falkowski et al did not find any association between 
variant genotypes of SLCO1B1 and 2B1 and CRC(Falkowski, Woillard et al. 2017).  
SNPs of genes involved in activation and metabolism of chemotherapeutic drugs. 
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Studies on the variants of genes involved in activation and metabolism of chemotherapeutic drugs have 
provided promising evidences to predict the outcome of treatment and drug response, as well as the 
potential for toxicity following chemotherapy.  
DPYD   
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in the pathway of uracil and 
thymidine catabolism. DPD catabolizes approximately 85% of 5-FU in CRC patients receiving 5-FU and 
defects in its function increases the risk of 5-FU toxic accumulation.  Molecular defects of DPYD gene 
lead to the deficiency of DPD activity(Dean 2016). Studies on DPYD gene polymorphisms provide 
promising evidences to predict toxicity following chemotherapeutic regimes in CRC patients. Graziano 
et al in the randomized phase III TOSCA trial analyzed 9 DPYD polymorphisms in 195 CRC patient who 
were treated with either FOLFOX-4 or XELOX for 3 or 6 months. The interval between the onset of 
treatment and the first severe toxicity was shorter with GA rs1801160 compared to GG genotype and 
GA rs3918290 compared to GG genotype for neutropenia. Also it was in a shorter timescale with CT 
rs1801265 genotype compared to TT genotype for diarrhea and was longer in presence of allele C (TC 
or CC) conferred for neurotoxicity(Graziano, Ruzzo et al. 2016). Also a  novel mutation 464 T>A was 
identified in DPYD gene by Morel et al  which was related to severe diarrhea, mucositis, leucopoenia, 
thrombocytopenia, and dehydration(Morel, Boisdron-Celle et al. 2007) . 
Meulendijks et al undertook a meta-analysis of the results of 8 studies including 7365 patients from 
eight studies. They report that DPYD c.1679T>G (rs55886062) and c.1236G>A/HapB3 (rs56038477) was 
significantly related to fluoropyrimidine-associated gastrointestinal and hematological toxicity. They 
recommended screening of DPYD variants c.1679T>G and c.1236G>A/HapB3 to improve the safety of 
patients who treated with fluoropyrimidines(Meulendijks, Henricks et al. 2015). Lee et al genotyped 
2886 patients with stage III colon cancer received FOLFOX or FOLFIRI regimes alone or combined with 
cetuximab. They showed an association between DPYD variants and adverse event (AE); the rs3918290 
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SNP was associated with specific AEs including nausea/vomiting and neutropenia whereas rs67376798 
was associated with dehydration, diarrhea, leukopenia, neutropenia and thrombocytopenia(Lee, Shi et 
al. 2014).  
TYMS & TYMP & TS  
Thymidylate synthetase (TYMS) and thymidine phosphorylase (TYMP) are fluorouracil-associated 
enzymes. It has been shown that overexpression of TYMS is associated with resistance to 5-FU 
chemotherapy and may lead to poorer DFS and OS(Koumarianou, Tzeveleki et al. 2014). TYMP play a 
role in regulation of pyrimidine metabolism in the cell. Evidences show that TYMP plays an important 
role in angiogenesis and extracellular matrix remodeling(Mitselou, Ioachim et al. 2012).  
There was no relationship between TYMS double or triple tandem repeats and early recurrence of  CRC 
in patients treated by 5-FU and leucovorin (Huang, Fang et al. 2008). A meta-analysis study of 2402 CRC 
patients for the most commonly studied SNP of TYMS, rs45445694 and indicated that the rs45445694 
SNP is associated with effects on protein expression, clinical benefit and adverse effects. However, the 
clinical utility limited because of the effect size was small(Jennings, Kwok et al. 2012).  
Thymidylate synthase (TS) is an important target for 5-FU; it is inhibited by FdUMP. FdUMP forms a 
stable ternary complex with TS and methyl-tetra-hydrofolic acid (MTHF/CH2THF). TS down-regulation 
improve the efficacy of the 5-FU(Ijichi, Adachi et al. 2014). Sarasqueta et al genotyped variable number 
of SNPs of TS gene in 251 patients with stage III colon carcinoma, but they indicated that TS gene 
polymorphisms is not a good candidate to predict the outcome of 5-FU treatment(Farina-Sarasqueta, 
Gosens et al. 2010). But another study showed that TS-3'-UTR -6/-6 carriers had a significantly longer 
OS in comparison with other genotype following modified FOLFOX6 treatment(Kumamoto, Ishibashi et 
al. 2013). 
UGT & Top1 
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Two important enzymes involved in metabolism and activation of irinotecan are UDP 
glucuronosyltransferase (UGT) and Topoisomerase 1 (Top1) respectively. UGT is a cytosolic 
glycosyltransferase enzyme that catalyzes glucuronidation reaction. Glucuronidation is the main 
metabolic pathway of irinotecan (CPT-11) and has been shown to protect against its toxicity. 
Responsible of irinotecan induced toxicity is SN-38 (7-Ethyl-10-hydroxycamptothecin) that is the 
pharmacologically active metabolite. UDP-glucuronosyltransferase1A (UGT1A) is the main enzyme 
involved in the glucuronidation of SN-38 to inactive metabolite, SN-38G. Evidences show that SNPs of 
UGT1A are important factors in irinotecan metabolism and are associated with higher rates of 
irinotecan related toxicity including neutropenia(Goetz, McKean et al. 2013). McLeod et al showed an 
association between the homozygous UGT1A1*28 allele and severe neutropenia in 520 advanced CRC 
patients who treated with irinotecan plus oxaliplatin (IROX)(McLeod, Sargent et al. 2010). Similarity 
Lévesque et al showed that three SNPs located in the central region of UGT1A are related to 
neutropenia after irinotecan therapy. They propose that these SNPs a are used for pharmacogenetic 
testing(Lévesque, Bélanger et al. 2013). Also another study showed an association between the 
homozygous UGT1A1*28 allele and severe neutropenia in patients who treated with irinotecan plus 
oxaliplatin (IROX)(McLeod, Sargent et al. 2010). However Falkowski et al did not find any associations 
between CRC SNPs in UGT1A6–9 and UGT2B7 genes (Falkowski, Woillard et al. 2017). But they found a 
relationship between UGT1A8 rs1042597-G, environmental risk factors and CRC so that carriers of the 
UGT1A8 rs1042597-G variant allele in the subgroup of meat-consumers had an increased CRC 
risk(Falkowski, Woillard et al. 2017).  
Marcuello1 et al designed a trial with the aim of determining the maximum tolerated dose of irinotecan 
according to UGT1A1 genotype. The maximum dose tolerated by patients was 450 mg/m2 in patients 
with the UGT1A1*1/*1 genotype, 390 mg/m2 in patients with the UGT1A1*1/*28 genotype, but only 
to 150 mg/m2 in patients with the UGT1A1*28/*28 genotype. Significantly lower response rates (RR) 
was observed in patients with UGT1A1*28/*28 genotype (13%) in comparison with UGT1A1*1/*1 
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(60%) and UGT1A1*1/*28 (39%) (Marcuello, Paez et al. 2011). However Dias et al perform a systematic 
review and meta-analysis to analyze the association between different UGT1A1*28 genotypes and 
objective response rate (ORR) in irinotecan-administered cancer patients. They showed that 
UGT1A1*28 polymorphism is unlikely factor to effect on response to irinotecan(Dias, McKinnon et al. 
2012).  
 Topoisomerase 1 (Top1) is an enzyme inhibits by irinotecan. It is an essential nuclear enzyme involved 
in DNA replication, transcription, translation, recombination and repair. Paolicchi analyzed two SNPs of 
Topoisomerase 1 (topo-1) gene including rs6072249 and rs34282819 to find the benefit from irinotecan 
in mCRC patients, but they find no correlation with clinical parameters (OS and PFS)(Paolicchi, Vivaldi et 
al. 2016) 
GSTM1 & GSTP1 
Glutathione S-transferase Mu 1 (GSTM1) and Glutathione S-transferase P (GSTP1) belong to the 
Glutathione S-transferase family that play an important role in detoxification compounds including 
carcinogens, therapeutic drugs and toxins. GSTM1 and GSTP1 genetic variations play a role in 
susceptibility to cancer, as well as effect on toxicity and efficacy of chemotherapeutic drugs(Sharma, 
Singh et al. 2015). Deletion in GSTM1 was related to severe neutropenia and GSTP1 homozygous 
variant genotype was related to neurotoxicity after FOLFOX therapy in CRC patients(McLeod, Sargent et 
al. 2010). 
The copy number of GSTM1 DNA is associated with survival in CRC patients treated with 
chemotherapy; so that mortality was significantly decreased in patients with one GSTM1 copy and non-
significantly decreased in those with the null genotype in comparison with carriers of two copies(Funke, 
Timofeeva et al. 2010). 
Sarasqueta et al showed that the A>G rs1695 polymorphism in the GSTP1 gene is more frequent in men 
than in women. They indicated that AA rs1695 in GSTP1 gene may have a prognostic value in male CRC 
11 
 
patients treated with oxaliplatin. So that homozygous AA rs1695 in men had significantly worse cancer-
specific survival and OS than women with the same genotype. However they suggested that SNPs in 
GSTP1 gene are not a reliable marker of the response to oxaliplatin therapy(Sarasqueta, van 
Lijnschoten et al. 2011). Similarity Le Morvan et al indicated that rs1695 in GSTP1 gene had no 
association with event-free and OS in patients treated by oxaliplatin or irrinotecan based 
chemotherapy(Le Morvan, Smith et al. 2007). Also Zaanan et al did not observed any association 
between GSTP1 polymorphisms rs1695 and DFS(Zaanan, Dalban et al. 2014). Another study confirmed 
that the rs1695 is not a reliable marker for predicting treatment outcomes in patients with CRC(Huang, 
Fang et al. 2008). In addition a meta-analysis in twelve prospective trials and two retrospective clinical 
trials (sample size: 2,191 ) showed no significant correlation between rs1695 and oxaliplatin-induced 
neuropathy(Peng, Wang et al. 2013).However McLeod et al indicated that AArs1695 carriers are more 
likely to discontinue FOLFOX because of neurotoxicity(McLeod, Sargent et al. 2010). Also another study 
showed that AArs1695 carriers had poor responses to mFOLFOX6 treatment in comparison with A/G & 
G/G genotypes(Kumamoto, Ishibashi et al. 2013). 
SNPs of genes involved in DNA repair and synthesis 
DNA excision repair protein (ERCC-1) and X-ray repair cross-complementing protein 1(XRCC1) are two 
proteins that are involved in DNA repair. ERCC1 is combined with ERCC4 to form a complex that 
participates in DNA repair and DNA recombination. Also XRCC1 is a scaffolding protein interacts with 
multiple repair enzymes(Carrera-Lasfuentes, Lanas et al. 2017). 
The CC rs11615 polymorphism in the ERCC1 gene and GG rs25487 in XRCC1 gene are associated with a 
better PFS and OS respectively in CRC patients. In addition, the carriers of both of these genotypes have 
better PFS and OS than those with only one or any of them.(Huang, Huang et al. 2011). Conversely 
Zaanan et al showed that carriers of TC/T rs11615 in ERCC1 gene versus CC and AA rs25487 in XRCC1 
gene versus GG/A had longer disease-free survival (DFS). Also carrier patients at least one variant allele 
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in rs1052559 in ERCC2 gene who treated with oxaliplatin based chemotherapy had shorter OS than 
those having no variant allele(Le Morvan, Smith et al. 2007). A combination of favorable genotypes 
showed better result in DFS(Zaanan, Dalban et al. 2014). Also Sarasqueta et al showed that 
A>C rs13181 in ERCC2 gene is more frequent in women than in men, but they indicated that none of 
the polymorphism in ERCC2 gene had effect on disease-free survival following oxaliplatin 
therapy(Sarasqueta, van Lijnschoten et al. 2011). But another study showed that the median PFS of 
AArs13181 carrier tended to be longer than ACrs13181 carrier in 63 CRC patients who received 
modified FOFOX(mFOLFOX)(Kumamoto, Ishibashi et al. 2013) 
Methylene tetrahydrofolate reductase (MTHFR) is the rate-limiting enzyme in the methyl cycle, 
involved in DNA synthesis. It has been shown that TT rs1801133  carriers are at an increased risk 
for CRC (Bailey 2003). Custodio et al performed genotyping of 32 genes involved in chemotherapeutic 
drug response for 67 SNPs in tumor samples of CRC patients receiving oxaliplatin-based chemotherapy. 
They showed that the combination of TT rs1801133 and G>A G/G rs3917412 genotypes in MTHFR and 
selectin E (SELE) respectively is related to increased risk for recurrence(Custodio, Moreno-Rubio et al. 
2014). However Huang et al did not show any relationship between C>T rs1801133 and risk of CRC 
recurrence in 201 CRC patients treated by 5-FU and leucovorin (Huang, Fang et al. 2008).  
SNPs and their lack of association with clinical outcomes in CRC 
In spite of the results of studies that indicate SNPs are related to clinical outcomes of CRC, there are 
other studies that indicate there is no relationship. This emphasizes the importance of further 
investigation in this issue. It seems that GWAS in different populations have a good response to drug 
selection and dose based on hereditary features(Fernandez-Rozadilla, Cazier et al. 2013). 
Falkowski et al investigated associations between CRC and Fifteen SNPs in UGT1A6–9, UGT2B7, ABCB1, 
ABCC2, SLCO1B1 and SLCO2B1 genes and correlated them with environmental risk factors in 300 CRC 
patients and 300 matched controls.  There was no significant evidence of an association between the 
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analyzed SNPs and risk of CRC. (Falkowski, Woillard et al. 2017). Gerber et al also performed 
quantitative genotyping of 16 SNPs including rs10411210, rs10936599, rs11169552, rs16892766, 
rs3802842, rs4444235, rs4779584, rs4939827, rs6687758, rs6691170, rs6983267, rs7014346, 
rs7136702, rs719725, rs961253, rs9929218 in 194 paired CRC and normal DNA samples for discovery 
set and 296 paired for validation set. These SNPs showed statistically significant association with CRC in 
published GWAS. But their results indicated that there was no statistically significant evidence for 
allele-specific somatic selection. However, the G allele of rs6983267 belong to cancer susceptibility 8 
(CASC8) gene was related to significant evidence of relative retention(Gerber, Hampel et al. 2012). 
Furthermore Kanai et al investigate the association between severity of peripheral sensory 
neuropathyand (PSN) and 12 SNPs (rs3114018 (ABCG2), rs843748 (ACYP2), rs4936453 (BTG4), 
rs2230641 (CCNH), rs12023000 (CAMK2N1), rs797519 (DLEU7), rs17140129 (FARS2), rs2338 (FOXC1), 
rs1695 (GSTP1), rs830884 (ITGA1) and rs10486003 (TAC1), rs25487 (XRCC1)) in a prospective 
pharmacogenomics study in 84 Japanese patients who failed to complete FOLFOX therapy. Their result 
shows no clinical significant between PSN and any of the 12 SNPs(Kanai, Kawaguchi et al. 2016). 
McLeod et al extracted germline DNA from 520 advanced CRC patients and 34 variants in 15 genes 
were assessed for adverse events or treatment outcome. They did not confirm most previously 
published genotype toxicity or efficacy association(McLeod, Sargent et al. 2010). A GWAS by 
Fernandez-Rozadilla et al in 221 CRC patients and a validation set of 791 patients who had been treated 
with 5-FU with/without oxaliplatin (FOLFOX), showed that 7 SNPs including rs16857540, rs2465403, 
rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761 associated with adverse drug 
reactions (ADRs)(Fernandez-Rozadilla, Cazier et al. 2013). 
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Conclusion 
Colorectal cancer remains an important cause of cancer related mortality, despite extensive efforts to 
treat the disease. In advanced stages, CRC therapy is based on systemic administration of anticancer 
drugs. But systemic anticancer therapies have limitations including drug resistance and life-threatening 
side effects. Therefore, researchers are trying to find biomarkers that act as a tool to select the optimal 
drug type and appropriate dose with the lowest possible toxicity, based on individual's characteristics. 
The major obstacle in designing anticancer regimens is genetic variation among individuals and various 
patterns of gene expression. Although the concept of cancer therapy base on individual's DNA 
sequences has not yet been accepted as a standard approach clinically, however it is the title of 
innumerable sciences articles. A large number of publications have shown that polymorphism in the 
genes responsible for activating, metabolizing, and determining the drug concentration in the cell plays 
an important role in determining the treatment outcome. It seems that in the future development of 
molecular pharmacological, biotechnology and genetics revolutionize the principles of anti-cancer 
therapy based on individual's characteristics. 
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Table 1: SNPs and their relationship to CRC anticancer drug treatment outcomes 
Gen Genotype Variant Effect Treatment Regime Subjects   
Number  
Ref 
ABCB1  CT  rs1045642 ↑Risk of CRC  
↓Time to recurrence 
FOLFOX, Xelox,  LV5–
FU2 and FUP 
1028 CRC patients 
and 1230 controls. 
(Wu, Kang et al. 
2013) 
ABCB1 GT 
GA 
rs2032582 ↑Risk of CRC  
 
FOLFOX, Xelox, LV5–
FU2 and FUP 
1028 CRC patients 
and 1230 controls. 
(Wu, Kang et al. 
2013) 
ABCB1 T T T rs1045642 
rs1128503 
rs2032582 
haplotype 
↑Risk of CRC  
 
 
FOLFOX, Xelox, LV5–
FU2 and FUP 
1028 CRC patients 
and 1230 controls. 
(Wu, Kang et al. 
2013) 
ABCB1 CT rs1128503 ↑OS  FOLFOX, Xelox, LV5–
FU2 and FUP 
1028 CRC patients 
and 1230 controls. 
(Wu, Kang et al. 
2013) 
ABCB1 TT-TT-TT 
 
rs1128503 
rs2032582 
rs1045642 
haplotype 
↓ PFS  
↑Recurrence-Free 
Survival 
FOLFOX, Xelox, LV5–
FU2 and FUP 
1028 CRC patients 
and 1230 controls. 
(Wu, Kang et al. 
2013) 
ABCB1  rs1045642 No Effect Oxaliplatin and 
Fluoropyrimidine-Based 
Adjuvant Chemotherapy 
202 (stage II and III) 
Validation set: 
independent cohort 
of 177 patients 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
ABCB1 GT rs2032582 ↑Levels of SN-38 irinotecan with/without 
cisplatin- 
Monotherapy: 55  
combination 
therapy: 62  
(Sai, Saito et al. 
2010) 
ABCB1 G > T/A rs2032582 ↑OS FOLFIRI 71  (De Mattia, 
Toffoli et al. 
2013) 
ABCB1 ABCB1 rs1045642 ↑Risk of toxicity  irinotecan and 5-FU 140 (Glimelius, 
Garmo et al. 
2011) 
ABCB1 T-T-T rs1128503  
rs2032582  
rs1045642  
haplotype 
↓OS 
 
irinotecan and 5-FU 140 (Glimelius, 
Garmo et al. 
2011) 
ABCB1  rs1045642  No Effect 5FU and leucovorin 201 (Huang, Fang et 
al. 2008) 
ABCC2 CC rs717620 Longer PFS FOLFIRI 61 (Akiyama, Fujita 
et al. 2012) 
ABCC10 minor 
alleles 
rs2125739 ↑Risk of death oxaliplatin 623 (201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
ABCG2  rs2231142 No Effect Oxaliplatin and 
Fluoropyrimidine-Based 
Adjuvant Chemotherapy 
202 (stage II and III) 
Validation set: 
independent cohort 
of 177 patients 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
ABCG2  rs2728124 No Effect Oxaliplatin and 
Fluoropyrimidine-Based 
Adjuvant Chemotherapy 
202 (stage II and III) 
Validation set: 
independent cohort 
of 177 patients 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
ABCG2  rs3114018 No Effect Oxaliplatin and 
Fluoropyrimidine-Based 
Adjuvant Chemotherapy 
202 (stage II and III) 
Validation set: 
independent cohort 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
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of 177 patients 
ABCG2 C > T rs7699188 Predictive of the RR FOLFIRI 71  (De Mattia, 
Toffoli et al. 
2013) 
SLCO1B1 GA/AA rs2306283 Higher rapid response 
rate 
↑PFS 
FOLFIRI or mCapeIRI 137 (Huang, Zhang et 
al. 2013) 
SLC19A1 GG rs1051266 Higher rapid response 
rate 
FOLFIRI or mCapeIRI 137 (Huang, Zhang et 
al. 2013) 
Intergenic GT rs6983267 Significant evidence 
of relative retention 
 194 paired normal 
and CRC DNA 
samples  
validation set : 296 
paired samples 
(Gerber, Hampel 
et al. 2012) 
ANXA11 TT rs1049550 Greater 
chemosensitive 
Bevacizumab+ FOLFIRI 98  (Kim, Kim et al. 
2011) 
LINS1 G rs11247226 Greater 
chemosensitive 
Bevacizumab + FOLFOX 98 (Kim, Kim et al. 
2011) 
DFNB31 GG rs2274159  Greater 
chemosensitive 
Cetuximab + FOLFIRI 98 (Kim, Kim et al. 
2011) 
LIFR GG rs3729740 Greater 
chemosensitive 
Cetuximab + FOLFIRI 98 (Kim, Kim et al. 
2011) 
EGFR GG rs1050171 ↑PFS Cetuximab and/or 
Panitumumab 
98 (Bonin, Donada 
et al. 2016) 
ERCC1 CC rs11615 ↑PFS FOLFOX-4 157  (Huang, Huang 
et al. 2011) 
ERCC1 CT & TT rs11615 ↑DFS versus CC FOLFOX 210 (Zaanan, Dalban 
et al. 2014) 
ERCC2 one variant 
allele 
rs1052559 ↓OS  
 
oxaliplatin based 
chemotherapy 
59 (Le Morvan, 
Smith et al. 
2007) 
ERCC2 AC rs13181 ↑risk of recurrence 5FU and leucovorin 201 (Huang, Fang et 
al. 2008) 
ERCC2 AA rs13181 ↑PFS  mFOLFOX6 63 (Kumamoto, 
Ishibashi et al. 
2013) 
ERCC5 AA -763AA ↑PFS and OS oxaliplatin-based 
chemotherapy 
170  (Chen, Luo et al. 
2016) 
ERCC5 GG +25GG ↑PFS and OS oxaliplatin-based 
chemotherapy 
170 (Chen, Luo et al. 
2016) 
XRCC1 GG rs25487 ↑PFS and OS FOLFOX-4 157  (Huang, Huang 
et al. 2011) 
XRCC1 AA rs25487 ↑DFS versus GG & 
GA 
FOLFOX  210 (Zaanan, Dalban 
et al. 2014) 
MTHFR C>T 
 
rs1801133  No effect on 
prediction 
↓Toxicity in 5-FU 
treatment. 
5-FU/leucovorin 331 (stage II–III) 37 
stage IV 
(Afzal, Jensen et 
al. 2009) 
MTHFR TT rs1801133 No effect  oxaliplatin-based 202 (stage II and III)  
Validation set: 177 
(cohort) 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
MTHFR A>C rs1801131 Do not predict 
efficacy of adjuvant 
5-FU   
5-FU/leucovorin 331 (stage II–III) 37 
stage IV 
(Afzal, Jensen et 
al. 2009) 
MTHFR C>T rs1801133 No effect  5-FU/leucovorin 201 (Huang, Fang et 
al. 2008) 
Selectin E G>A GG 
 
rs3917412 
 
↑Risk for recurrence oxaliplatin-based 202 (stage II and III)  
Validation set: 177 
(cohort) 
(Custodio, 
Moreno-Rubio et 
al. 2014) 
topo-1 AA,AC,CC rs6072249 No effect FOLFIRI ± bevacizumab 105  (Paolicchi, 
Vivaldi et al. 
2016) 
topo-1 AA,AG,GG rs34282819 No effect FOLFIRI ± bevacizumab 105  (Paolicchi, 
Vivaldi et al. 
2016) 
ATP1A1 minor 
allele 
rs975351 ↓Risk of death oxaliplatin 623 (201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
ATP8B3 minor 
allele 
rs7249302 ↓Risk of death oxaliplatin 623 (201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
ATP1B2 minor  
allele 
rs1642763 ↓Risk of death oxaliplatin  623 (201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
ATP8B3 minor  
allele 
rs8100856 ↓Risk of death oxaliplatin 623 (201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
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GSTP1 AA rs1695 ↓OS in men oxaliplatin 98  (Sarasqueta, van 
Lijnschoten et al. 
2011) 
GSTP1  rs1695 No effect on event-
free and OS  
oxaliplatin or irrinotecan 
based chemotherapy 
107 (Le Morvan, 
Smith et al. 
2007) 
GSTP1  rs1695 No effect on DFS FOLFOX 210 (Zaanan, Dalban 
et al. 2014) 
GSTP1 AA rs1695 poor responses  mFOLFOX6 63 (Kumamoto, 
Ishibashi et al. 
2013) 
GSTM1 
Deletion 
One copy  ↑OS 
 
Chemotherapy for 36.4 
months. 65 patients 
received oxaliplatin 
338 (Funke, 
Timofeeva et al. 
2010) 
GSTM5 minor alleles rs11807 ↑risk of death oxaliplatin 623 
(201 patients 
received oxaliplatin) 
(Kap, Seibold et 
al. 2016) 
UGT1A1 28 allele rs8175347 ↓RR irrinotecan 94 (Marcuello, Paez 
et al. 2011) 
UGT1A1 28 allele rs8175347 No association with 
RR  
irrinotecan 1898 (Dias, McKinnon 
et al. 2012) 
TYMS  rs45445694 protein expression, 
clinical benefit, 
adverse effects 
 2402 (Jennings, Kwok 
et al. 2012) 
TYMS  double or triple 
tandem repeats 
No effect 5-FU and leucovorin 201 (Huang, Fang et 
al. 2008) 
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Table 2 :SNPs and their relationship to toxicity following CRC anticancer drugs 
Gen genotype Variant Effect Treatment 
Regime  
Number of 
Subjects 
Ref 
ABCC5 CC rs562 GI Toxicity Irinotecan 26  (Di Martino, Arbitrio et 
al. 2011) 
ABCG1 GG rs425215 GI Toxicity Irinotecan 26  (Di Martino, Arbitrio et 
al. 2011) 
ABCG2  rs7699788 Nonhematological FOLFIRI 71  (De Mattia, Toffoli et al. 
2013) 
OaTP1B1/
SLCO1B1 
GA rs2306283 GI Toxicity Irinotecan 26  (Di Martino, Arbitrio et 
al. 2011) 
UGT1A1 C>T homozygous 3156  Neutropenia IROX 520  (McLeod, Sargent et al. 
2010) 
UGT1A1 28 allele rs8175347 Neutropenia IROX 520  (McLeod, Sargent et al. 
2010) 
UGT1A 
 
28 allele rs8175347 
 
Hematologic Toxicity 
Febrile Neutropenia 
 167 
 
(Lévesque, Bélanger et al. 
2013) 
UGT1A 1A9/1A7/
1A1 
haplotype 
HII 
 
UGT1A1*28 
Neutropenia 
 
5-U/Irinotecan-
Based regimen 
167 
 
(Lévesque, Bélanger et al. 
2013) 
UGT1A  rs2070959 Neutropenia 
 
5-U/Irinotecan-
Based regimen 
167 
 
(Lévesque, Bélanger et al. 
2013) 
UGT1A  rs11692021 Neutropenia 
 
5-U/Irinotecan-
Based regimen 
167 
 
(Lévesque, Bélanger et al. 
2013) 
UGT1A  UGT1A9 c.-688 Neutropenia 5-U/Irinotecan-
Based regimen 
167 (Lévesque, Bélanger et al. 
2013) 
GSTM1  Deletion  Neutropenia  FOLFOX 520  (McLeod, Sargent et al. 
2010) 
GSTP1  Homozygous 
Variant Genotype  
Neurotoxicity FOLFOX 520  (McLeod, Sargent et al. 
2010) 
GSTP1 AA rs1695 Neurotoxicity FOLFOX 520 (McLeod, Sargent et al. 
2010) 
DPYD G/A rs1801160 Neutropenia FOLFOX-4 / 
XELOX 
195  (Graziano, Ruzzo et al. 
2016) 
DPYD G/A rs3918290 Neutropenia FOLFOX-4 / 
XELOX 
195  (Graziano, Ruzzo et al. 
2016) 
DPYD C/T rs1801265  Diarrhoea FOLFOX-4 / 
XELOX 
195  (Graziano, Ruzzo et al. 
2016) 
DPYD T>A 464 Diarrhoea, 
Mucositis  
Leucopoenia 
Thrombocytopaenia,  
Dehydration 
5-FU / 
Leucovorin 
a 73-year-old 
woman 
(Morel, Boisdron-Celle et 
al. 2007) 
DPYD  A/A 
A/G 
rs3918290 Nausea/Vomiting  
Neutropenia 
FOLFOX or 
FOLFIRI 
±cetuximab 
2886 (stage 
III) 
(Lee, Shi et al. 2014) 
DPYD  A>T rs67376798 Dehydration 
Diarrhea 
Leukopenia 
Neutropenia 
Thrombocytopenia 
FOLFOX or 
FOLFIRI 
±cetuximab 
2886 (stage 
III) 
(Lee, Shi et al. 2014) 
22 
 
 
 
NLGN1  rs16857540 Mucositis 5-FU 221  
validation 
set: 791  
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
COLEC10  rs2465403 Mucositis 5-FU 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
PARD3B  rs17626122 Haematologic FOLFOX 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
Intergenic 
Locations 
 rs10876844 Diarrhoea 5-FU 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
Intergenic 
Locations 
 rs10784749 Diarrhoea 5-FU 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
Intergenic 
Locations 
 rs7325568 Haematologic FOLFOX 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
Intergenic 
Locations 
 rs4243761 Haematologic FOLFOX 221  
validation 
set: 791 
(Fernandez-Rozadilla, 
Cazier et al. 2013) 
